Tryptamine Therapeutics (ASX:TYP) has finished dosing the first patient with psilocin using an IV drip in a global first.
The company is conducting the trial alongside CMAX Clinical Research in Adelaide.
Running with the drug name TRP-8803, the company is now setting out to figure out optimal dosing amounts and infusion times of the compound to achieve “precise blood levels.”
Up to 12 participants will form part of this trial. The first patient dosed saw the drug infused over 140 minutes – just over two hours. The patient “progressed well” and was discharged on completion, the company reported on Monday.
Notably, the company reported its TRP-8803 includes one key advantage: a “significant reduction in onset of the psychedelic state.” In layman’s terms, that means patients will be less likely to freak out.
The company also wants to make sure that the duration of effects – “intervention” – are on a “commercially feasible timeframe.”
As in, patients will be over and done with tripping in a relatively short window (presumably two hours) as opposed to the likely overwhelming 12 hours of fun LSD and other drugs offer users.
The trial is expected to be wound up in Q3 of 2024 with results to follow.
TYP last traded at 2.1cps.